Bulk Inquiry
AG14361
- Soluble in 0.1N HCl(aq), DMSO and EtOH
- MF: C19H20N4O
- MW: 320.39
Description
AG14361 is a potent PARP1 inhibitor with a Ki value of 5.8 nM (human full-length PARP1). Moreover, AG14361 is the first high-potency PARP1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.
More Information
| Parent CAS No. | 328543-09-5 |
|---|---|
| Chemical Name | 2-[4-[(Dimethylamino)methyl]phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one |
| SMILES | C1C2C(=O)NCCN3C(C4=CC=C(CN(C)C)C=C4)=NC(C=23)=CC=1 |
| MFCD | MFCD18385009 |
| InChi | InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24) |
| InChiKey | SEKJSSBJKFLZIT-UHFFFAOYSA-N |
| CID | 9840076 |
| Short Description | PARP1 inhibitor |
References
- DJ Skalitzky et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
- CR Calabrese et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1268 | DR 2313 |
From $99.00 |
| 1370 | NU 1025 |
From $88.00 |
| 1464 | Olaparib |
From $55.00 |
| 1496 | 3-Aminobenzamide |
From $44.00 |
| 1529 | AG 014699 |
From $66.00 |
| 1566 | Iniparib |
From $66.00 |
| 1593 | Veliparib |
From $44.00 |
| 2001 | KU-0058948 hydrochloride |
From $148.50 |
| 2241 | AZD2461 |
From $104.50 |
| 2369 | UPF 1069 |
From $82.50 |
| 2502 | Talazoparib |
From $99.00 |
| 2537 | 1,5-Isoquinolinediol |
From $55.00 |
| 2759 | ME0328 |
From $104.50 |
| 2885 | GeA-69 |
From $104.50 |
| 2888 | Veliparib dihydrochloride |
From $99.00 |
| 2928 | Niraparib |
From $99.00 |
| 3113 | Rucaparib camsylate |
From $99.00 |
| 3398 | E7449 mesylate |
From $121.00 |
| 4179 | KU-0058948 |
From $148.50 |
| 4435 | RBN-2397 |
From $198.00 |
